Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy

Pediatr Blood Cancer. 2024 Jul;71(7):e31036. doi: 10.1002/pbc.31036. Epub 2024 Apr 28.

Authors

Masanaka Sugiyama¹, Ayumu Arakawa^{1

2}, Shintaro Iwata^{2

3}, Kayoko Tao¹, Nami Shirakawa¹, Yuko Watanabe¹, Miho Nakajima¹, Akihiko Yoshida⁴, Keiko Ishigaki⁵, Akira Kawai^{2

3}, Chitose Ogawa^{1

2}

Affiliations

¹ Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
² Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.
³ Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan.
⁴ Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
⁵ Department of Pediatrics, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.

PMID: 38679860
DOI: 10.1002/pbc.31036

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Combined Modality Therapy
Feasibility Studies
Humans
Male
Rhabdomyosarcoma* / pathology
Rhabdomyosarcoma* / therapy
Walker-Warburg Syndrome / genetics
Walker-Warburg Syndrome / therapy